Europe
The two companies will seek approval for the biologic as a treatment for severe atopic dermatitis in children ages six to 11.
Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology
The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros.
AI Design enables new bispecific small molecule modality
CELLINK AB has entered an agreement with the owners of cytena GmbH to acquire all cytena shares for a purchase price of 30.25M euros.
New ‘Vilnius-Made’ method reduces DNA testing costs by 90%, while the city’s long-standing tradition of life sciences further position Lithuanian Capital as emerging European hub of international scientific development
Company strengthens board ahead of trial results in type 1 diabetes patients and expansion of indications for its proprietary Imotope™ technology
First patient enrolment at University of Cincinnati
Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease.
Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics.
PRESS RELEASES